Antibody targeting of Cathepsin S induces antibody-dependent cellular cytotoxicity
- Hang Fai Kwok1Email author,
- Richard J Buick1Email author,
- Diana Kuehn1,
- Julie A Gormley1,
- Declan Doherty1,
- Thomas J Jaquin1,
- Angela McClurg1,
- Claire Ward1,
- Teresa Byrne1,
- Jacob Jaworski1,
- Ka Lai Leung1,
- Philip Snoddy1,
- Christine McAnally1,
- Roberta E Burden1, 2,
- Breena Gray1,
- Jenny Lowry1,
- Isabelle Sermadiras1,
- Natalia Gruszka1,
- Nigel Courtenay-Luck1,
- Adrien Kissenpfennig3,
- Christopher J Scott2,
- James A Johnston1, 3 and
- Shane A Olwill1
© Kwok et al; licensee BioMed Central Ltd. 2011
Received: 16 August 2011
Accepted: 14 December 2011
Published: 14 December 2011
Proteolytic enzymes have been implicated in driving tumor progression by means of their cancer cell microenvironment activity where they promote proliferation, differentiation, apoptosis, migration, and invasion. Therapeutic strategies have focused on attenuating their activity using small molecule inhibitors, but the association of proteases with the cell surface during cancer progression opens up the possibility of targeting these using antibody dependent cellular cytotoxicity (ADCC). Cathepsin S is a lysosomal cysteine protease that promotes the growth and invasion of tumour and endothelial cells during cancer progression. Our analysis of colorectal cancer patient biopsies shows that cathepsin S associates with the cell membrane indicating a potential for ADCC targeting.
Here we report the cell surface characterization of cathepsin S and the development of a humanized antibody (Fsn0503h) with immune effector function and a stable in vivo half-life of 274 hours. Cathepsin S is expressed on the surface of tumor cells representative of colorectal and pancreatic cancer (23%-79% positive expression). Furthermore the binding of Fsn0503h to surface associated cathepsin S results in natural killer (NK) cell targeted tumor killing. In a colorectal cancer model Fsn0503h elicits a 22% cytotoxic effect.
This data highlights the potential to target cell surface associated enzymes, such as cathepsin S, as therapeutic targets using antibodies capable of elicitingADCC in tumor cells.
KeywordsCathepsin S ADCC antibody protease microenvironment
Proteases regulate a number of pathways relevant to cancer biology, including proliferation, differentiation, apoptosis, migration, and invasion [1, 2]. In the last decade, it has become increasingly evident that tumor cells create a pericellular microenvironment where molecules such as metalloproteinases, cysteine proteases and serine proteases interact to form a pro-tumorigenic proteolytic network [2, 3]. Indeed the establishment of a causal relationship between enhanced activity or expression of proteases and tumor progression (e.g. through extracellular matrix remodelling) has promoted the development of many small molecule inhibitors as anticancer therapeutics. However clinical trials with many of these agents have been disappointing due to their off target effects coupled with poor bioavailability, leading drug developers to consider the use of biologic inhibitors (antibodies or peptides) [1, 4, 5]. There is an increasing body of evidence suggesting that proteases involved in cancer microenvironment which are normally found within intracellular compartments often relocate during tumor progression, resulting in secretion and association with binding partners on the tumor cell surface [6–9].
Cathepsin S is one of a family of eleven lysosome cysteine proteases normally restricted to the lysosomes of professional antigen presenting cells where it mediates cleavage of the invariant chain (li) from MHC class II complexes prior to antigen loading for presentation [10–12]. In cancer, cathepsin S is translocated from its normal intracellular lysosomal compartment into the extracellular milieu [13, 14]. Reports have shown that cathepsin S is stable at neutral pH and is potently elastin- and collagenolytic, promoting extracellular matrix remodelling, tumor growth and invasion in the tumor microenvironment [15, 16]. Enhanced cathepsin S expression and activity have been detected in several human cancers (glioma, breast, prostate, colorectal and pancreatic) with in vivo mouse models supporting its role in tumorigenesis [17–21]. The association of cathepsin S with colorectal cancer progression has been recently highlighted where it was shown to be a prognostic indicator . A number of groups have studied the mechanistic role of cathepsin S in cancer using in vitro and in vivo models [18, 21].
The potential of cathepsin S as a novel cancer target amenable to antibody mediated therapy has been examined using a murine anti-cathepsin S monoclonal antibody (Fsn0503) which is capable of blocking tumor cell invasion, endothelial tube formation and microvascular sprouting during angiogenesis [23, 24]. While previous reports had suggested that cathepsin S is found either in the lysosomal lumen or secreted into the ECM, our analysis of colorectal cancer patient biopsies and cancer cell lines show that it is also associated with the cell membrane indicating a potential for antibody dependant cellular cytotoxicity (ADCC) targeting.
ADCC relies on a mechanism of Fc effector domain recruitment of immune cells (e.g. Natural Killer) to tumor cells with surface bound antibody. Advances in recombinant antibody engineering facilitate the introduction of immune effector function for those antibodies which target cell surface antigens [25, 26].
In the present study, we show that cathepsin S is on the surface of tumour cells and that this localization can be exploited with a fully human IgG1 version of Fsn0503 (Fsn0503h) to induce ADCC, demonstrating the clinical potential of the engineered cathepsin S specific human antibody Fsn0503h.
Cathepsin S is expressed on the surface of Colorectal Cancer (CRC) tumor cells
To further assess the translocation of cathepsin S from intracellular compartments to the cell surface, cancer cell lines (Colo205, LoVo, BxPC-3 and Aspc-1) were analysed by confocal microscopy. In all cell lines, intense cathepsin S staining co-localizes with actin at focal points on the cell membrane mirroring the expression pattern observed in patient biopsy samples (Figure 3C & 3D). This suggests a concentrated localization of cathepsin S at specific areas of the cell surface. This expression pattern of localised regions of high antigen density is observed in a subset of cells potentially indicating tight regulation of surface expression. In some cases, cathepsin S expression can be observed in protrusions of the cell membrane, potentially areas of exocytosis.
Humanization and characterization of Fsn0503
ADCC of Fsn0503h in colon and pancreatic carcinoma cell line
Here we demonstrate expression of cathepsin S on the surface of pancreatic and colon carcinoma cells. In addition, we reveal how cell surface associated cathepsin S can be targeted to mediate ADCC by a fully humanized anti-cathepsin S antibody, Fsn0503h. To the best of our knowledge this is the first example of a protease or surface enzyme being targeted to elicit ADCC.
Cathepsin S is a cysteine protease that plays a key role in invasion, angiogenesis and metastasis during tumor progression [21, 27–29]. In normal conditions, cathepsin S has limited tissue distribution and is found primarily in lysosomal compartments of professional antigen presenting cells; however it is up-regulated and secreted into the microenvironment during tumor development [11, 21]. Based on our findings, we postulate that during tumorigenesis, a proportion of secreted cathepsin S associates with the tumour cell surface. Cathepsin B has previously been shown to localize to the cell surface . Under normal circumstances cathepsin B, a house-keeping enzyme, is located in perinuclear lysosomes but in cancer it is secreted and relocalized to the plasma membrane. While the exact mechanisms underlying intracellular enzyme shuttling of cathepsins remain to be elucidated it is thought that mannose-6-phosphate receptors (MPR) may play a role albeit via discrete pathways for individual family members . Under certain conditions, including reduced pH, lysosomes may fuse with the plasma membrane, thus becoming secretory organelles, which facilitate association with the cell surface . This membrane association is supported by our flow cytometry findings which show on average 23-79% of Colo205, LoVo, BxPC-3 and ASPC1 cells express cell surface cathepsin S. IHC analysis of patient biopsies further demonstrate cell surface localization of cathepsin S where staining is characterized by a distinct polarization to either the basal or apical epithelial membrane. Confocal analysis of cancer cell line models also support this association as cathepsin S was observed to localize to the cell surface membrane with intense staining restricted to specific regions. A pattern of regional expression has also been reported for other proteases involved in tumorigenesis which have been shown to congregate in caveolae. Caveolae have multiple proteolytic factors (e.g. cathepsins, annexins, uPA, MMP's) which represent concentrated membrane sub-domains (protease pools) that facilitate organized cell surface proteolysis . As well as facilitating co-operation between different proteases the concentration of cathepsin S in focal micro-domains, results in regions of high antigen density, which can beused to induce ADCC.
As discussed above, Fsn0503 is a murine IgG1κ antibody, shown to have anti-tumor efficacy in xenograft models through inhibition of cathepsin S mature protein. The murine IgG1 isotype has negligible ADCC potential and has the added drawback that if administered to patients undergoing immunotherapy may result in a strong human anti-mouse antibody (HAMA) response with rapid clearance. To make the antibody suitable for clinical utility we have developed a fully human version. The majority of therapeutic antibodies are human IgG1 isotypes (e.g. Herceptin and Cetumximab), particularly in oncology as it facilitates the introduction of additional effector function. IgG1 allows engagement of immune effector cells through binding of Fc receptors (FcγR) expressed on NK cells, macrophages and polymorphonuclear leukocytes with the NK population identified as the principal instigator of ADCC [34–36]. IgG4 isotype antibodies such as natalizumab (Tysabri) are more commonly used in applications where cell killing is not the objective, such as multiple sclerosis or rheumatoid arthritis. Based on our findings that cathepsin S is associated to the surface of the tumour cells we engineered a human antibody with ADCC functionality. Through the use of a specific human IgG1 framework the recombinant antibody, Fsn0503h with an in vivo half-life of approximately 11.4 days (274 hours), has the potential to recruit NK cells via the FcγRIIIa (CD16a)and to actively kill tumor cells in patients . In order to evaluate the ADCC effector function of Fsn0503h we performed ex vivo activity assays using healthy donor peripheral blood mononuclear cells as it is difficult to obtain meaningful data from current in vivo murine models. Human IgG1 antibodies have much reduced ADCC activity in mouse xenograft models due to differing species immune cell recognition patterns [37, 38]. We chose to assess the effector function of our human antibody using a well characterized LDH release assay and demonstrated that Fsn0503h is capable of eliciting greater than 20% specific cytotoxic cell kill in the LoVo colorectal cancer model. Furthermore with the use of an anti-CD16 neutralising antibody we have shown that the ADCC functionality of Fsn0503h works through the recruitment of CD16 positive immune cells such as human NK cells to induce tumour cell death.
Currently twenty-two therapeutic antibodies have been approved by the US Food and Drug Administration (FDA), at least eleven of which are for the treatment of cancer [39, 40]. While antibodies such as rituximab have proven very efficacious for the treatment of leukaemia the clinical impact of drugs such as cetuximab (anti-EGFR) and bevacizumab (anti- VEGF) in solid tumors has, however, been less dramatic. A reason for this may be the limited penetration of antibodies into the tumor but also an under appreciation of potential effector function. To improve upon existing therapies recombinant antibodies which have been optimized to elicit immune effector function (e.g. ADCC) are now emerging as a major new class of drugs . With this in mind it is important to assess all potential mechanisms of killing for any novel drug. The identification of novel cancer targets will help to broaden the number of patients for which antibody-based immunotherapy may be effective. The demonstration of cathepsin S targeted ADCC efficacy opens up the possibility of targeting other enzymes (such as MMP's, ADAMs) in a similar way. Antibodies such as Fsn0503h, combining immune effector function with the ability to specifically block protease activity as demonstrated in our previous published data , may have significant clinical utilityfor the treatment of cancer.
In summary, we demonstrate expression of cathepsin S on the surface of pancreatic and colon carcinoma cells and reveal how cell surface associated cathepsin S can be targeted to mediate ADCC by a fully humanized anti-cathepsin S antibody, Fsn0503h. This is the first example of a protease or surface enzyme being targeted to elicit ADCC. This data highlights the potential to target cell surface associated enzymes as therapeutic targets using antibodies capable of eliciting ADCC in tumor cells.
Materials and Methods
Cancer cell lines
The human cancer cell lines (Colo205, LoVo, BxPC-3, Panc-1 and Aspc-1) were purchased from American Type Culture Collection (ATCC, Rockville, MD). The colon carcinoma cell lines, Colo205 and LoVo, were cultured in RPMI 1640 medium (Sigma Aldrich, UK) and F-12K medium (Invitrogen, UK) respectively, supplemented with 10% foetal calf serum (FCS) (PAA, Laboratories, Somerset, UK) and L-glutamine (10 nmol/L) (Invitrogen, UK). BxPC-3, Aspc-1 and Panc-1 (pancreatic carcinoma) were cultured in RPMI 1640 medium (Invitrogen, UK) supplemented with 10% foetal calf serum (FCS) (PAA, Laboratories, Somerset, UK) and L-glutamine (10 nmol/L) (Invitrogen, UK). All cultures were maintained in a humidified environment at 37°C with 5% CO2.
Immunohistochemistry (IHC) staining
Tissue microarray sections, containing biopsy cores taken from colorectal cancer patient specimens, were stained for cathepsin S as previously described  using an automated IHC platform (Bond Max™, Leica Microsystems, Newcastle, UK). Mouse anti-cathepsin S antibody Fsn0503 (Fusion Antibodies Ltd.) was used at 4 ug/mL. A polymer-based detection system (Refine cat#DS9800) was used with 3',3-Diaminobenzidine (DAB) as the chromogen.
Western blotting and Flow cytometry
To prepare whole cell lysates of Colo205, LoVo, BxPC-3, Aspc-1 and Panc-1, cell pellets were washed in PBS and lysed using standard RIPA buffer supplemented with a Calbiochem® protease inhibitor cocktail set III (1:50 dilution of lysis buffer) (Merck Chemicals Ltd., UK) as previously described . Samples were incubated for 30 minutes on ice prior to a 20 minute centrifugation at 13,000 rpm. Protein concentration was determined by BCA assay (Thermo Scientific, UK). Denatured samples were analysed by SDS-PAGE on 12% (w/v) polyacrylamide gels. Gels were transferred by semi-dry blotting onto nitrocellulose membrane, blocked with 3% dried milk before probing with 0.4 μg mouse anti-Cathepsin S antibody in 15 mL PBS overnight 4°C. Following washes in phosphate-buffered saline tween (PBS-T), membranes were probed with goat anti-mouse-HRP (1:3000) (Bio-Rad Laboratories Ltd., UK) for 1 hour at room temperature. After a series of further washes with PBS-T, membranes were developed using Chemiluminescent Substrate (West Pico Chemiluminescent Substrate, Pierce) for 5 minutes.
The surface expression of cathepsin S on Colo205, LoVo, BxPC-3, Aspc-1 and Panc-1 cell lines was examined and quantified by flow cytometry. Briefly, cells (0.5 × 106) were washed with cold Cell Wash (BD Biosciences, UK) and incubated with 0.5μg of polyclonal goat anti-cathepsin S antibody (R&D Systems, UK) in PBS for 1.5 hour on ice. The cells were then washed with cold Cell Wash and incubated with R-PE-conjugated donkey anti-goat antibody (1:50) (Abcam, UK) in PBS for 1 hour on ice. The cells were washed with cold PBS and stored at 4°C in the dark prior to analysis on the FACSCanto (BD Biosciences, UK). Target quantification was performed using QuantiBRITE PE beads (BD Biosciences, UK). Briefly, QuantiBRITE PE beads were run on the BD FACSCanto using the same parameters for fluorescence as used for the analysis of the cell lines. Geometric means were displayed in the statistic view (BD FACS Diva Software v6.1) and the calculation of Antibody Bound per Cell (ABC) values was carried out according to the manufacturer's protocol.
To assess localized cathepsin S expression Colo205, LoVo, BxPC-3, Aspc-1 and Panc-1 cells were grown on coverslips at 20,0000 cells/well in a humidified environment at 37°C with 5% CO2 overnight. The cells were then rinsed with Cell Wash (BD Biosciences, UK) and fixed with 4% paraformaldehyde (PFA) for 15 minutes at room temperature. After fixing, the cells were washed with PBS and non-specific sites were quenched with a blocking buffer (PBS containing 10% goat serum) for 2 hours. The cells were then incubated with 32 μg of mouse anti-cathepsin S antibody Fsn0503 or mouse isotype antibody control (Fusion Antibodies Ltd., UK) for 1 hour at 37°C. After extensive rinsing with PBS, the cells were incubated with 10 μg/mL goat anti-mouse AlexFlour 488-conjugated secondary antibody (Invitrogen, UK) in blocking buffer for 1 hour in the dark. Labelling of actin filaments was performed with Molecular Probes® rhodamine phalloidin (1:150) (Invitrogen, UK). After extensive washing, the coverslips were mounted upside-down on glass microscope slides using Vectashield® media (Vector Laboratories Inc., Burlingame, CA, USA) and viewed on laser confocal microscope.
Humanization of the murine antibody
mRNA was extracted from 106 cells of Fsn0503 using STAT60 reagent. RT-PCR was performed using an oligo(dT) primer and reverse transcriptase, followed by PCR with murine specific IgG degenerate primers. The PCR products were cloned into the pCR2.1 vector (Invitrogen) for sequencing analysis. The vector was transformed into TOP10 cells and positive clones identified by PCR. The plasmid clones were mini-prepped and sequenced by the dideoxy-chain termination method on an ABI 3130xl genetic analyser. A consensus sequence for the light chain and heavy chain variable domains was determined from a minimum of 5 clones.
A Composite Human Antibody™ version of the Fsn0503 antibody, Fsn0503h, was designed from multiple human antibody sequences, with CDRs (complementarity Determining Regions) identified using Kabat and Chothia definitions (REF). The composite sequence was screened for T cell epitopes binding to human MHC Class II alleles (Antitope). The Fsn0503h VH and VL sequences were synthetically constructed and cloned into an expression vector containing human IgG1 isotype constant domains. Human IgG1 isotype was selected as the optimum isotype for ADCC activity in humans. NS01 cells were stably transfected via electroporation with both heavy chain and light chain expression vectors. Electroporated cells were distributed into 5 × 96 well plates and selected with 200 nM MTX (methotrexate). Wells containing methotrexate resistant colonies were sampled and tested for IgG expression levels, and the best expressing line was selected and frozen down (Antitope). Fsn0503h was then further selected by two rounds of limiting dilution in 96 well plates in the presence of 200 nM MTX. Fsn0503h cells were cultured in Dulbeccos Minimum Essential medium (Invitrogen, Paisley, UK) supplemented with 10% Ultra Low IgG serum (Invitrogen, Paisley, UK), 1% Penicillin Streptomycin (PAA laboratories, Austria), and 200 nM methotrexate (Sigma, Poole, UK). Cells were cultured in T-flasks (Greiner, GmbH). Cells were routinely passaged twice a week at ratios between 1:3 and 1:6 according to the cell density. To express large quantities of antibodycells were seeded in T-175 flasks at a seeding density of 3.0-5.0 × 104 cells/cm2 in 30 mL of complete DMEM. Cells were incubated at 37°C 6% CO2 for 11 days prior to harvesting of culture medium by centrifugation at 5,000 g for 40 minutes. Antibody was purified on a protein A column (GE Healthcare, UK) using AKTA prime chromatography system (GE Healthcare, UK).
A PK study was performed to assess the stability and half-life of Fsn0503h in serum. All animal experiments were carried out in accordance with the Animal (Scientific Procedures) Act 1986 and conformed to current UK Co-ordinating Committee on Cancer Research guidelines. Eight week old male and female Sprague-Dawley (SD) rats (three male; three female), were housed in a temperature and humidity-controlled room for the duration of the study. Blood samples (pre-bleed) were taken from each animal before treatment with Fsn0503h. Each animal was administrated with 10 mg/kg Fsn0503h by intravenous (i.v.) tail injection. Blood samples (0.5 - 1 mL) were collected in heparinised tubes at selected time points following administration of Fsn0503h: 1, 4, 24, 48 hours, then once a week (7, 21, 28, 35, 42 days). Samples were centrifuged following collection, and serum was stored at -20°C until analysis by ELISA. Briefly, recombinant human cathepsin S was coated onto a 96-well plate (40 nM) and incubated with varying dilutions of serum or drug standards for 1 hour at room temperature. After rinsing with PBS-T secondary antibody (rat anti-human horseradish peroxidase-conjugated antibody) was added to each well. Plates were incubated for 1 hour at room temperature, washed with PBS-T and then incubated with TMB for 5 minutes at room temperature. The reaction was stopped by the addition of 500 mmol/L HCL, and absorbance was read at 450 nm.
ADCC was determined by conducting a standard CytoTox 96® Non-Radioactive Cytotoxicity LDH-Release Assay purchased from Promega. The LoVo colorectal cancer cell line and BxPC3 pancreatic cancer cell line were selected for analysis. The LoVo and BxPC-3 cells were seeded at 7000 cells/well. Human peripheral blood mononuclear cells (PBMCs) obtained from healthy donors were used as effectors cells following IL-2 stimulation (100 U/mL). Both the target (T) and effector (E) cells were resuspended in 5% FCS RPMI medium with 15 mM HEPES and incubated in triplicate on 96-well microtiter plates with various concentrations of Fsn0503h (from 6670 to 833.75 nM) with or without CD16 neutralizing antibody (6670 nM) at an E:T cell ratio of 40:1.
Statistical analysis was performed on experimental results using the student t test of variance. All in vitro/ex vivo experiments were repeated a minimum of three times and datais expressed as means ± SD.
We would like to thank the Technical Department, Fusion Antibodies Ltd for production of Fsn0503h and other reagents. The authors would also like to thank the staff of Queen University Belfast BRU/CTU for assistance with preclinical studies and immunohistochemistry. Thanks to Alan Green and Surinder Sharma at University College London, Cancer Institute for their advice on PK study design and statistics. This work was sponsored by Fusion Antibodies Ltd and was part funded through an Invest Northern Ireland European Regional Development Fund grant (RD1208028).
- Egeblad M, Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002, 2: 161-174. 10.1038/nrc745View ArticlePubMedGoogle Scholar
- Webb SL, Sanders AJ, Mason MD, Jiang WG: Type II transmembrane serine protease (TTSP) deregulation in cancer. Front Biosci. 2011, 16: 539-552. 10.2741/3704View ArticleGoogle Scholar
- Guo H, Li R, Zucker S, Toole BP: EMMPRIN (CD147), an inducer of matrix metalloproteinase synthesis, also binds interstitial collagenase to the tumor cell surface. Cancer Res. 2000, 60: 888-891.PubMedGoogle Scholar
- Rubin H: Complementary approaches to understanding the role of proteases and their natural inhibitors in neoplastic development: retrospect and prospect. Carcinogenesis. 2003, 24: 803-816. 10.1093/carcin/bgg020View ArticlePubMedGoogle Scholar
- Scott CJ, Taggart CC: Biologic protease inhibitors as novel therapeutic agents. Biochimie. 2010, 92: 1681-1688. 10.1016/j.biochi.2010.03.010View ArticlePubMedGoogle Scholar
- Hanahan D, Weinberg RA: The hallmarks of cancer. Cell. 2000, 100: 57-70. 10.1016/S0092-8674(00)81683-9View ArticlePubMedGoogle Scholar
- Hu M, Yao J, Carroll DK, Weremowicz S, Chen H, Carrasco D, Richardson A, Violette S, Nikolskaya T, Nikolsky Y, Bauerlein EL, Hahn WC, Gelman RS, Allred C, Bissell MJ, Schnitt S, Polyak K: Regulation of in situ to invasive breast carcinoma transition. Cancer Cell. 2008, 13: 394-406. 10.1016/j.ccr.2008.03.007PubMed CentralView ArticlePubMedGoogle Scholar
- Peng CW, Liu XL, Liu X, Li Y: Co-evolution of cancer microenvironment reveals distinctive patterns of gastric cancer invasion: laboratory evidence and clinical significance. J Transl Med. 2010, 8: 101- 10.1186/1479-5876-8-101PubMed CentralView ArticlePubMedGoogle Scholar
- Van Goethem E, Poincloux R, Gauffre F, Maridonneau-Parini I, Le Cabec V: Matrix architecture dictates three-dimensional migration modes of human macrophages: differential involvement of proteases and podosome-like structures. J Immunol. 2010, 184: 1049-1061. 10.4049/jimmunol.0902223View ArticlePubMedGoogle Scholar
- Nakagawa TY, Brissette WH, Lira PD, Griffiths RJ, Petrushova N, Stock J, McNeish JD, Eastman SE, Howard ED, Clarke SR, Rosloniec EF, Elliott EA, Rudensky AY: Impaired invariant chain degradation and antigen presentation and diminished collagen-induced arthritis in cathepsin S null mice. Immunity. 1999, 10: 207-217. 10.1016/S1074-7613(00)80021-7View ArticlePubMedGoogle Scholar
- Shi GP, Villadangos JA, Dranoff G, Small C, Gu L, Haley KJ, Riese R, Ploegh HL, Chapman HA: Cathepsin S required for normal MHC class II peptide loading and germinal center development. Immunity. 1999, 10: 197-206. 10.1016/S1074-7613(00)80020-5View ArticlePubMedGoogle Scholar
- Riese RJ, Wolf PR, Brömme D, Natkin LR, Villadangos JA, Ploegh HL, Chapman HA: Essential role for cathepsin S in MHC class II-associated invariant chain processing and peptide loading. Immunity. 1996, 4: 357-366. 10.1016/S1074-7613(00)80249-6View ArticlePubMedGoogle Scholar
- Mort JS, Recklies AD, Poole AR: Release of cathepsin B precursors from human and murine tumours. Prog Clin Biol Res. 1985, 180: 243-245.PubMedGoogle Scholar
- Mai J, Finley RL, Waisman DM, Sloane BF: Human procathepsin B interacts with the annexin II tetramer on the surface of tumor cells. J Biol Chem. 2000, 275: 12806-12812. 10.1074/jbc.275.17.12806View ArticlePubMedGoogle Scholar
- Shi GP, Munger JS, Meara JP, Rich DH, Chapman HA: Molecular cloning and expression of human alveolar macrophage cathepsin S, an elastinolytic cysteine protease. J Biol Chem. 1992, 267: 7258-7262.PubMedGoogle Scholar
- Petanceska S, Canoll P, Devi LA: Expression of rat cathepsin S in phagocytic cells. J Biol Chem. 1996, 271: 4403-4409. 10.1074/jbc.271.8.4403View ArticlePubMedGoogle Scholar
- Flannery T, Gibson D, Mirakhur M, McQuaid S, Greenan C, Trimble A, Walker B, McCormick D, Johnston PG: The Clinical Significance of Cathepsin S Expression in Human Astrocytomas. Am J Pathol. 2003, 163: 175-182. 10.1016/S0002-9440(10)63641-3PubMed CentralView ArticlePubMedGoogle Scholar
- Joyce JA, Baruch A, Chehaed K, Meyer-Morse N, Giraudo E, Tsai FY, Greenbaum D, Hager JH, Bogyo M, Hanahan D: Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell. 2004, 5: 443-453. 10.1016/S1535-6108(04)00111-4View ArticlePubMedGoogle Scholar
- Jedeszko C, Sloane BF: Cysteine cathepsins in human cancer. Biol Chem. 2004, 385: 1017-1027. 10.1515/BC.2004.132View ArticlePubMedGoogle Scholar
- Ryschich E, Lizdenis P, Ittrich C, Benner A, Stahl S, Hamann A, Schmidt J, Knolle P, Arnold B, Hammerling GJ, Ganss R: Molecular fingerprinting and autocrine growth regulation of endothelial cells in a murine model of hepatocellular carcinoma. Cancer Res. 2006, 66: 198-211. 10.1158/0008-5472.CAN-05-1636View ArticlePubMedGoogle Scholar
- Gocheva V, Zeng W, Ke D, Klimstra D, Reinheckel T, Peters C, Hanahan D, Joyce JA: Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes Dev. 2006, 20: 543-556. 10.1101/gad.1407406PubMed CentralView ArticlePubMedGoogle Scholar
- Gormley JA, Hegarty SM, O'Grady A, Stevenson MR, Burden RE, Barrett HL, Scott CJ, Johnston JA, Wilson RH, Kay EW, Johnston PG, Olwill SA: The role of Cathepsin S as a marker of prognosis and predictor of chemotherapy benefit in adjuvant CRC: a pilot study. Br J Cancer. 2011, 105: 1487-1494. 10.1038/bjc.2011.408PubMed CentralView ArticlePubMedGoogle Scholar
- Burden RE, Gormley JA, Jaquin TJ, Small DM, Quinn DJ, Hegarty SM, Ward C, Walker B, Johnston JA, Olwill SA, Scott CJ: Antibody-mediated inhibition of cathepsin S blocks colorectal tumor invasion and angiogenesis. Clin Cancer Res. 2009, 15: 6042-6050. 10.1158/1078-0432.CCR-09-1262View ArticlePubMedGoogle Scholar
- Ward C, Kuehn D, Burden RE, Gormley JA, Jaquin TJ, Gazdoiu M, Small D, Bicknell R, Johnston JA, Scott CJ, Olwill SA: Antibody targeting of cathepsin S inhibits angiogenesis and synergistically enhances anti-VEGF. PLoS One. 2010, 5: e12543-10.1371/journal.pone.0012543. 10.1371/journal.pone.0012543PubMed CentralView ArticlePubMedGoogle Scholar
- Hawkins RE, Llewelyn MB, Russell SJ: Adapting antibodies for clinical use. BMJ. 1992, 305: 1348-1352. 10.1136/bmj.305.6865.1348PubMed CentralView ArticlePubMedGoogle Scholar
- Carter PJ: Potent antibody therapeutics by design. Nat Rev Immunol. 2006, 6: 343-357. 10.1038/nri1837View ArticlePubMedGoogle Scholar
- Podgorski I, Sloane BF: Cathepsin B and its role(s) in cancer progression. Biochem Soc Symp. 2003, 70: 263-276.View ArticlePubMedGoogle Scholar
- Bell-McGuinn KM, Garfall AL, Bogyo M, Hanahan D, Joyce JA: Inhibition of cysteine cathepsin protease activity enhances chemotherapy regimens by decreasing tumor growth and invasiveness in a mouse model of multistage cancer. Cancer Res. 2007, 67: 7378-7385. 10.1158/0008-5472.CAN-07-0602View ArticlePubMedGoogle Scholar
- Palermo C, Joyce JA: Cysteine cathepsin proteases as pharmacological targets in cancer. Trends Pharmacol Sci. 2008, 29: 22-28. 10.1016/j.tips.2007.10.011View ArticlePubMedGoogle Scholar
- Sloane BF, Rozhin J, Johnson K, Taylor H, Crissman JD, Honn KV: Cathepsin B: association with plasma membrane in metastatic tumors. Proc Natl Acad Sci. 1986, 83: 2483-2487. 10.1073/pnas.83.8.2483PubMed CentralView ArticlePubMedGoogle Scholar
- Sameni M, Elliott E, Ziegler G, Fortgens PH, Dennison C, Sloane BF: Cathepsin B and D are Localized at the Surface of Human Breast Cancer Cells. Pathol Oncol Res. 1995, 1: 43-53. 10.1007/BF02893583View ArticlePubMedGoogle Scholar
- Sloane BF, Moin K, Sameni M, Tail LR, Rozhin J, Ziegler G: Membrane association of cathepsin B can be induced by transfection of human breast epithelial cells with c-Ha-ras oncogene. J Cell Sci. 1994, 107: 373-384.PubMedGoogle Scholar
- Cavallo-Medved D, Sloane BF: Cell-surface cathepsin B: understanding its functional significance. Cell surface protease. Edited by: Zucker S, Chen WT. 2003, 313-325. New York: Academic Press,Google Scholar
- van de Winkel JG, Capel PJ: Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications. Immunol Today. 1993, 14: 215-221. 10.1016/0167-5699(93)90166-IView ArticlePubMedGoogle Scholar
- Clynes RA, Towers TL, Presta LG, Ravetch JV: Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med. 2000, 6: 443-446. 10.1038/74704View ArticlePubMedGoogle Scholar
- van Ojik HH, Bevaart L, Dahle CE, Bakker A, Jansen MJ, van Vugt MJ, van de Winkel JG, Weiner GJ: CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations. Cancer Res. 2003, 63: 5595-5600.PubMedGoogle Scholar
- Lutterbuese P, Brischwein K, Hofmeister R, Crommer S, Lorenczewski G, Petersen L, Lippold S, da Silva A, Locher M, Baeuerle PA, Schlereth B: Exchanging human Fcgamma1 with murine Fcgamma2a highly potentiates anti-tumor activity of anti-EpCAM antibody adecatumumab in a syngeneic mouse lung metastasis model. Cancer Immunol Immunother. 2007, 56: 459-468. 10.1007/s00262-006-0218-7View ArticlePubMedGoogle Scholar
- Stavenhagen JB, Gorlatov S, Tuaillon N, Rankin CT, Li H, Burke S, Huang L, Vijh S, Johnson S, Bonvini E, Koenig S: Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors. Cancer Res. 2007, 67: 8882-8890. 10.1158/0008-5472.CAN-07-0696View ArticlePubMedGoogle Scholar
- Reichert JM, Valge-Archer VE: Development trends for monoclonal antibody cancer therapeutics. Nat Rev Drug Discov. 2007, 6: 349-356. 10.1038/nrd2241View ArticlePubMedGoogle Scholar
- Yamane-Ohnuki N, Satoh M: Production of therapeutic antibodies with controlled fucosylation. mAbs. 2009, 1: 230-236. 10.4161/mabs.1.3.8328PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.